Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang, Tao; Cao, Linlin; Jiang, Qikun; Zhang, Tianhong

doi:10.3389/fphar.2021.749858

Cited by 18 publications

(20 citation statements)

References 203 publications

(344 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 Wang T et al also state that fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a preferred option for the treatment of glaucoma. 18 Thelen U studies to evaluate the effect of an "escalation" of topical glaucoma therapy by switching from prostaglandin monotherapy…”

Section: Discussionmentioning

confidence: 99%

Relationship between Progressive Cup Disc Ratio and Intraocular Pressure in Primary Open Angle Glaucoma After 2 Antiglaucoma Agents for 3 Months

Syafridon

Fidalia²,

Sari³

2022

sjo

View full text Add to dashboard Cite

Introduction: Primary open-angle glaucoma (POAG) is a subset of glaucoma defined by an open, normal-appearing anterior chamber angle and raised intraocular pressure (IOP) with no other underlying disease. Globally 57.5 million people were affected by primary open-angle glaucoma (POAG) in 2015, rising to 65.5 million by 2020. POAG can further lead to optic nerve damage, which can cause total blindness. POAG cannot be cured but can be controlled with medical therapy, laser, and surgical procedures. Antiglaucoma drugs are a method of treatment that can overcome this disease. This study aims to determine the characteristics of patients with POAG and progressivity of cup to disc ratio and intraocular pressure after 3 months of management of 2 antiglaucoma agents in POAG patients in Dr. Mohammad Hoesin General Hospital Palembang. Methods: This study retrospectively reviewed the medical records specific to primary open-angle glaucoma. Data was obtained from the patient register book recorded from February 2022 to May 2022 in Dr. Mohammad Hoesin General Hospital Palembang. The parameters analyzed were patients' profiles, namely gender, intraocular pressure, and cup to disc ratio before and after 3 months of combination 2 antiglaucoma agents. Timolol and latanoprost are the 2 antiglaucoma agents given to patients diagnosed of previous POAG (by an ophthalmologist). Results: From 30 patients diagnosed with POAG by an ophthalmologist, the number of primary open-angle glaucoma patients was more female, namely 19 patients (63.3%) than 11 male patients (36.7%), with a ratio of 1.28:1 between women and men. The cup to disc ratio between before and after 3 months of therapy using timolol and latanoprost was 0.628 ± 0.04 before therapy to 0.645 ± 0.06 after therapy (p<0.05). Intraocular pressure before and after 3 months of therapy was 24.76 ± 2.63 before therapy to 17.75 ± 2.08 (p<0,05). Both cup to disc ratio and intraocular pressure differs statistically from before and after therapy. Conclusion: Fixed combination therapy of timolol and latanoprost is effective in lowering intraocular pressure and reducing cup to disc ratio progressivity in patients with primary open-angle glaucoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between Progressive Cup Disc Ratio and Intraocular Pressure in Primary Open Angle Glaucoma After 2 Antiglaucoma Agents for 3 Months

Syafridon

Fidalia²,

Sari³

2022

sjo

View full text Add to dashboard Cite

show abstract

“…It was discovered that PGs reduce the IOP by enhancing the aqueous humor outflow, and the first antiglaucoma prostaglandin analog (PGA), latanoprost, received the Food and Drug Administration’s approval between August 2000 and March 2001 [ 6 ]. Now PGAs are considered the drugs of choice for the treatment of POAG [ 7 , 8 ]. Currently there are five PGAs marketed as aqueous eye drops.…”

Section: Introductionmentioning

confidence: 99%

Aqueous Prostaglandin Eye Drop Formulations

Jansook

Loftsson

2022

Pharmaceutics

View full text Add to dashboard Cite

Glaucoma is one of the leading causes of irreversible blindness worldwide. It is characterized by progressive optic neuropathy in association with damage to the optic nerve head and, subsequently, visual loss if it is left untreated. Among the drug classes used for the long-term treatment of open-angle glaucoma, prostaglandin analogues (PGAs) are the first-line treatment and are available as marketed eye drop formulations for intraocular pressure (IOP) reduction by increasing the trabecular and uveoscleral outflow. PGAs have low aqueous solubility and are very unstable (i.e., hydrolysis) in aqueous solutions, which may hamper their ocular bioavailability and decrease their chemical stability. Additionally, treatment with PGA in conventional eye drops is associated with adverse effects, such as conjunctival hyperemia and trichiasis. It has been a very challenging for formulation scientists to develop stable aqueous eye drop formulations that increase the PGAs’ solubility and enhance their therapeutic efficacy while simultaneously lowering their ocular side effects. Here the physiochemical properties and chemical stabilities of the commercially available PGAs are reviewed, and the compositions of their eye drop formulations are discussed. Furthermore, the novel PGA formulations for glaucoma treatment are reviewed.

show abstract

“…A potentially effective fixed-combination timolol (0.5%)-netarsudil (0.02%)-latanoprost (0.005%) ophthalmic solution (FC-TNL) could successfully lower IOP by targeting multiple mechanisms involved decreasing AH production and increasing AH outflow [5 , 21] . Therefore, once-daily FC-TNL can be more potentially to decrease dosing frequency, avoid drug washout, limit exposure to preservatives and reduce ocular discomfort.…”

Section: Introductionmentioning

confidence: 99%